Parkinson's Disease Therapies Accelerate with 200+ Candidates and 150 Companies
Over 150 companies are advancing more than 200 Parkinson's disease therapies. Research is increasingly focused on disease-modifying treatments.
The development of Parkinson's disease therapies is accelerating, with more than 150 companies advancing over 200 pipeline candidates targeting the underlying mechanisms of neurodegeneration. Companies such as Roche, Prothena Biosciences, and Annovis Bio are driving innovation in this field.
DelveInsight's report, "Parkinson's Disease Pipeline Insight, 2026," provides a comprehensive analysis of this rapidly evolving landscape. The report details clinical and non-clinical drug candidates, emerging therapeutic strategies, and competitive intelligence.
Parkinson's disease is a progressive neurological disorder affecting motor function due to the degeneration of dopamine-producing neurons. Despite existing symptomatic treatments, the lack of disease-modifying therapies represents a significant unmet need, driving extensive research and development.
Research is increasingly focusing on disease-modifying approaches targeting alpha-synuclein aggregation, neuroinflammation, and genetic mutations. Companies are advancing over 200 candidates across various development stages, from biologics and gene therapies to cell-based interventions.